Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates

Wolfe Research Continues to Favor Moderna's (MRNA) 'Significiant Upside Optionality' in its Broad Pipeline

May 4, 2022 10:22 AM EDT

Wolfe Research analyst Andrew Galler reiterated an Outperform rating and $261.00 price target on Moderna (NASDAQ: MRNA).

The analyst comments "At the time of our initiation in November 2021, the stock was coming off of a onetwo punch from a cut to COVID vaccine guidance and PFEs topline data for Paxlovid from the EPIC-HR study, but with increasing visibility into the booster opportunity (which has only been helped by the spread of the Omicron variant), the... More

Moderna (MRNA) Tops Q1 EPS by $3.37, Revenue Beats

May 4, 2022 6:54 AM EDT

Moderna (NASDAQ: MRNA) reported Q1 EPS of $8.58, $3.37 better than the analyst estimate of $5.21. Revenue for the quarter came in at $6.1 billion versus the consensus estimate of $4.62 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.

... More